Perforated diverticulitis associated with ocrelizumab infusion

[1]  X. Mariette,et al.  OP0022 RISK OF DIVERTICULITIS AND GASTRO-INTESTINAL PERFORATION IN RHEUMATOID ARTHRITIS TREATED WITH TOCILIZUMAB COMPARED TO RITUXIMAB AND ABATACEPT: A PROSPECTIVE PROPENSITY-MATCHED COHORT STUDY , 2020, Annals of the Rheumatic Diseases.

[2]  T. Dhere,et al.  First Case of Refractory Colitis Caused by Ocrelizumab. , 2020, Inflammatory bowel diseases.

[3]  M. Valasek,et al.  P096 DE NOVO COLITIS AFTER OCRELIZUMAB THERAPY , 2020, Gastroenterology.

[4]  Mehnaz A. Shafi,et al.  Clinical Features of Rituximab-associated Gastrointestinal Toxicities , 2019, American journal of clinical oncology.

[5]  X. Montalban,et al.  Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis , 2018, Journal of the Neurological Sciences.

[6]  M. Aringer,et al.  Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs , 2016, Annals of the rheumatic diseases.

[7]  S. Bernatsky,et al.  Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments , 2016, Arthritis & rheumatology.

[8]  L. Sollid,et al.  The intestinal B-cell response in celiac disease , 2012, Front. Immun..

[9]  M. Neurath,et al.  Exacerbation of ulcerative colitis after rituximab salvage therapy , 2007, Inflammatory bowel diseases.

[10]  J. James,et al.  FDA approves new kind of lymphoma treatment. Food and Drug Administration. , 1997, AIDS treatment news.